June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Blockade of Apelin Receptor (APJ) can inhibit developmental retinal vessel outgrowth in pups and promote normal revascularization and reduce pathological neovascularization in OIR model in mice
Author Affiliations & Notes
  • Eunice Cheung
    Regeneron Pharmaceuticals, Tarrytown, New York, United States
  • Panayiotis Stevis
    Regeneron Pharmaceuticals, Tarrytown, New York, United States
  • Yonaton Ray
    Regeneron Pharmaceuticals, Tarrytown, New York, United States
  • Stanley J Wiegand
    Regeneron Pharmaceuticals, Tarrytown, New York, United States
  • Carl Romano
    Regeneron Pharmaceuticals, Tarrytown, New York, United States
  • Ivan Lobov
    Regeneron Pharmaceuticals, Tarrytown, New York, United States
  • Footnotes
    Commercial Relationships   Eunice Cheung, Regeneron Pharmaceuticals, Inc. (E); Panayiotis Stevis, Regeneron Pharmaceuticals, Inc. (E); Yonaton Ray, Regeneron Pharmaceuticals, Inc. (E); Stanley Wiegand, Regeneron Pharmaceuticals, Inc. (E); Carl Romano, Regeneron Pharmaceuticals, Inc. (E); Ivan Lobov, Regeneron Pharmaceuticals, Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 194. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Eunice Cheung, Panayiotis Stevis, Yonaton Ray, Stanley J Wiegand, Carl Romano, Ivan Lobov; Blockade of Apelin Receptor (APJ) can inhibit developmental retinal vessel outgrowth in pups and promote normal revascularization and reduce pathological neovascularization in OIR model in mice. Invest. Ophthalmol. Vis. Sci. 2017;58(8):194.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : During angiogenesis, apelin/apelin receptor (APJ) in combination with VEGF, induces the proliferation and assembly of endothelial cells (H Kidoya, et al. EMBO J, 2008; 27). Much remains to be discovered about the expression of the apelinergic system and precisely how it affects numerous physiological functions. In this study, we evaluate apelin receptor inhibition in normal retinal vascular development and in oxygen retinopathy model (OIR) in mice.

Methods : Study 1: Humanized (Hu) ApelinR mice were systemically (IP) injected with 25 mg/kg and 50 mg/kg Fc (control) and anti-Apelin Receptor (αAR) at P2 and collected at P5;
Study 2: Repeat of Study 1 at the highest dose, analyzed by masked graders.
Study 3: P2 Hu pups were IP injected with 50 mg/kg Fc, αAR or aflibercept and collected at P5;
Study 4: Hu were place in a hyperoxic environment (75% O2) at P6 and returned to room air at P11. Pups were injected systemically with 50 mg/kg Fc (control), αAR, or aflibercept at P12 and collected at P16;
Study 5: OIR Hu mice were injected intravitreally (IVT) with 5 µg Fc, αAR, or aflibercept at P12 and collected at P16.
All retinas were stained with FITC-labeled Griffornia simplicifolia lectin I (Vector Laboratories).

Results : By injecting αAR at P2, vascular outgrowth was reduced by 23% (n= 6 eyes/groups, p < 0.05) at 25 mg/kg and 35% (n= 6 eyes/group, p < 0.005) at 50 mg/kg at P6. Aflibercept administration produced 43% reduction in blood vessel outgrowth at 50 mg/kg. In the OIR model, αAR and aflibercept were able to promote vessel regrowth. When pups were IP injected at OIR P12, αAR and aflibercept significantly reduced avascular areas by 29% and 27% (n= 6 eyes/group, p < 0.005) and neovascularizations by 69% and 94% (n= 6 eyes/group, p < 0.0001) at P16 respectively. With IVT administration aflibercept reduced vessel regrowth by 30% (n= 4 eyes/group, p < 0.0001) and eliminated all neovascularization, while αAR was able to promote vessel regrowth by 30% (n= 4 eyes/group, p < 0.0001) and reduce neovascularizations by 60% (n= 4 eyes/group, p < 0.0001).

Conclusions : Our data suggest that apelin/APJ is an important mediator of developmental angiogenesis and both pathologic and normal angiogenesis in hypoxia-driven proliferative retinopathy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×